Table 2 Clinical characteristics of pediatric COVID-19
From: Epidemiological and clinical features of pediatric COVID-19
| Classification | Characteristic (No., %) |
|---|---|
| Clinical diagnosis | 341 |
| Asymptomatic | 20 (5.9%) |
| With abnormal chest radiograph | 6 (30%) |
| Mild/moderate | 318 (99.3%) |
| Severe | 2 (0.6%) |
| Critical | 1 (0.3%) |
| Clinical symptoms | 136 |
| Fever (37.3~40 °C) | 106 (77.9%) |
| Cough | 44 (32.4%) |
| Lacrimation | 6 (4.4%) |
| Stuffy nose | 3 (2.2%) |
| Sneezing | 1 (0.7%) |
| Sore throat | 3 (2.2%) |
| Dyspnea | 3 (2.2%) |
| Nausea & vomiting | 4 (2.9%) |
| Diarrhea | 6 (4.4%) |
| Conjunctivitis | 1 (0.7%) |
| Dizziness and headache and myalgia | 3 (2.2%) |
| Fatigue | 3 (2.2%) |
| Body discomfort | 3 (2.2%) |
| Coexisting disorders | 136 |
| Congenital heart | 2 (1.5%) |
| Complications | 136 |
| Heart failure | 1 (0.7%) |
| Myocardial injury | 6 (4.4%) |
| Liver injury | 3 (2.2%) |
| Acute respiratory distress syndrome/shock/acute kidney injury | 1 (0.7%) |
| Treatment | 62 |
| Antiviral treatment | 33 (53.2%) |
| TCM | 27 (43.5%) |
| Antibiotic treatment | 17 (27.4%) |
| Nutritional support therapy | 17 (27.4%) |
| Symptomatic treatment | 17 (27.4%) |
| Interferon therapy | 7 (11.3%) |
| Immunoglobulin therapy | 4 (6.5%) |
| Psychological intervention | 2 (3.2%) |
| Not taking medicine | 1 (1.6%) |
| Glucocorticoid therapy | 1 (1.6%) |
| Mechanical ventilation | 1 (1.6%) |
| Clinical outcome | |
| Death | 0/341 |
| Time from onset to cure (days) | 218 |
| Median (range) | 16 (6–39) |
| Quartile (Q1–Q3) | 13–21 |
